Compare J M Smucker Co (SJM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs TG Therapeutics Inc — how do they compare? J M Smucker Co trades at $117.46 (market cap $12.54B), while TG Therapeutics Inc trades at $50 (market cap $7.64B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SJM | TGTX | |
|---|---|---|
Market Cap | $12.54B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $126.35 | $59.06 |
52-Week Low | $89.53 | $26.94 |
Enterprise Value | $19.57B | $7.84B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $118.84, up 0.65% today, with a bullish technical signal and support near $117. The company reported revenue of $8.73B in 2025 but a net loss of -$1.23B, though recent quarters show earnings beats. Analyst consensus is a Buy with a $125.11 price target, and the dividend was recently increased to $1.12 per share, marking 25 consecutive years of growth.
Outlook is mixed: strong cash flow and dividend growth support income investors, but negative margins and high debt pose risks. Upside depends on cost controls and Uncrustables growth offsetting sales declines. The stock offers value at a P/E of 22.05 but faces execution challenges in a competitive consumer staples market.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
